Fique a par dos últimos desenvolvimentos nas áreas da Alergologia e Imunologia Clínica no Congresso da EAACI de 2024 em Valência, Espanha
March 19, 2024 07:42 ET
|
European Academy of Allergy and Clinical Immunology
http://www.globenewswire.com/NewsRoom/AttachmentNg/d32f0dd2-5510-4922-aead-62719b31e294 VALÊNCIA, Espanha, March 19, 2024 (GLOBE NEWSWIRE) -- A Academia Europeia de Alergia e Imunologia...
Mengupas Kemajuan Terbaru dalam Alergi dan Imunologi Klinis pada Kongres EAACI 2024 di Valencia, Spanyol
March 19, 2024 07:42 ET
|
European Academy of Allergy and Clinical Immunology
http://www.globenewswire.com/NewsRoom/AttachmentNg/d32f0dd2-5510-4922-aead-62719b31e294 VALENCIA, Spanyol, March 19, 2024 (GLOBE NEWSWIRE) -- Akademi Alergi dan Imunologi Klinis Eropa (EAACI)...
報導於西班牙華倫西亞舉行的 EAACI Congress 2024（2024 年度歐洲過敏及臨床免疫學會大會）中，過敏症及臨床免疫學的最新動態
March 19, 2024 07:42 ET
|
European Academy of Allergy and Clinical Immunology
http://www.globenewswire.com/NewsRoom/AttachmentNg/d32f0dd2-5510-4922-aead-62719b31e294 華倫西亞，西班牙, March 19, 2024 (GLOBE NEWSWIRE) -- 來自全球 125 個國家及地區，會員人數逾 16,000 人的 European Academy of Allergy...
在巴伦西亚, 西班牙举行的 2024 年欧洲变态反应与临床免疫学学会大会上报道变态反应和临床免疫学的最新发展动态
March 19, 2024 07:42 ET
|
European Academy of Allergy and Clinical Immunology
http://www.globenewswire.com/NewsRoom/AttachmentNg/d32f0dd2-5510-4922-aead-62719b31e294 巴伦西亚, 西班牙, March 19, 2024 (GLOBE NEWSWIRE) -- 欧洲变态反应与临床免疫学学会 (EAACI) 拥有来自 125 个国家/地区的 16,000...
Sema4 to Participate at Two Investor Conferences in June 2022
May 26, 2022 08:00 ET
|
Sema4
STAMFORD, Conn., May 26, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced that company management will participate...
Sema4 Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 04, 2022 16:05 ET
|
Sema4
STAMFORD, Conn., May 04, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced that, effective as of May 2, 2022, the...
Sema4 Announces the Completion of the GeneDx Acquisition and a Streamlined Leadership Structure to Accelerate Growth of its Diagnostic and Clinical Data Platforms
May 02, 2022 07:45 ET
|
Sema4
Acquisition creates an AI-driven advanced health intelligence company, now leveraging one of the largest genomic testing platforms in the U.S. Katherine Stueland, former President and CEO of GeneDx,...
Sema4 to Report First Quarter 2022 Financial Results on Thursday, May 12, 2022
April 26, 2022 16:05 ET
|
Sema4
STAMFORD, Conn., April 26, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced it will release financial results for...
Sema4 Achieves HITRUST CSF Certification
April 06, 2022 08:00 ET
|
Sema4
STAMFORD, Conn., April 06, 2022 (GLOBE NEWSWIRE) -- Sema4 (NASDAQ: SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced that its health intelligence platform,...
Sema4 Announces Nationwide Expansion of Disparity Study to Deliver Precision Oncology Care to Underserved Communities
March 16, 2022 08:00 ET
|
Sema4
- The REPRESENT Study Will Create One of the Most Diverse and Comprehensive Clinico-genomic Datasets to Uncover and Address Disparities in Cancer Care - Sema4’s Chief Medical Science Officer Will...